System Accuracy Evaluation of 2 CE-marked Blood Glucose Monitoring System

Diabetes Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02710617
• Other study ID #: IDT-1542-IU
• Status: Completed
• Phase: N/A
• First received: March 11, 2016
• Last updated: August 30, 2016
• Start date: March 2016
• Est. completion date: May 2016

Study information

• Verified date: August 2016
• Source: Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

The objective of this study is the evaluation of system accuracy following ISO 15197:2013 (E), clause 6.3 in which accuracy requirements and applicable test procedures for blood glucose monitoring systems intended for self-monitoring of blood glucose by patients are stipulated.

However in this study, system accuracy evaluation will be performed for Hemocue Glucose 201+ and Hemocue Glucose 201 RT which are both glucose monitoring systems for professional use only on behalf of the IDT with one reagent system lot for each BGMS.

Main goal is the evaluation of system accuracy of both of the hemocue Systems. (english)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 109
• Est. completion date: May 2016
• Est. primary completion date: April 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female, with type 1 diabetes, type 2 diabetes or subjects without diabetes

• Signed informed consent form

• Minimum age of 18 years

• Subjects are legally competent and capable to understand character, meaning and consequences of the study.

• If blood glucose values < 80 mg/dl or > 300 mg/dl shall be measured after short term alteration in insulin therapy:

• Male or female with type 1 diabetes and intensified insulin therapy or insulin pump therapy.

• Signature of subjects to document consent with these procedures on informed consent form.

Exclusion Criteria:

• Pregnancy or lactation period

• Severe acute disease (at the study physician's discretion)

• Severe chronic disease with potential risk during the test procedures (at the study physician's discretion)

• Current constitution that compromises the subject's capability to participate in the study (at the study physician's discretion)

• Being unable to give informed consent

• < 18 years

• Legally incompetent

• Being committed to an institution (e.g. psychiatric clinic)

• Language barriers potentially compromising an adequate compliance with study procedures

• Dependent on investigator or sponsor

• If blood glucose values < 80 mg/dl shall be measured after short term alteration in insulin therapy (concentration category 2, see Fehler! Verweisquelle konnte nicht gefunden werden.), subjects with type 1 diabetes, suffering from:

• Coronary heart disease

• Condition after myocardial infarction

• Condition after cerebral events

• Peripheral arterial occlusive disease

• Hypoglycemia unawareness

Study Design

N/A

Related Conditions & MeSH terms

• Diabetes

Intervention

Device:
• Blood glucose monitoring systems for point-of-care-testing

Locations

Country	Name	City	State
Germany	Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm	Ulm

Sponsors (1)

Lead Sponsor	Collaborator
Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	System accuracy criteria (see description)	System accuracy criteria; Following ISO 15197:2013 (E), the BGMS shall meet both of the following criteria: Criterion A: 95 % of the measured glucose values shall fall within either ± 15 mg/dl (0.83 mmol/l) of the average comparison measurement result at glucose concentrations < 100 mg/dl (5.55 mmol/l) or within ± 15 % at glucose concentrations = 100 mg/dl (5.55 mmol/l).; Each lot shall pass acceptability criterion A.; Criterion B: 99 % of individual glucose measured values shall fall within zones A and B of the Consensus Error Grid (CEG) for type 1 diabetes.	For each subject, the experimental phase has an expected duration of up to 6 hours